An update from Lytix Biopharma AS ( (DE:6BG) ) is now available.
Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, presented promising data on Lytix’s lead drug candidate, LTX-315, at the Winter Clinical Dermatology Conference. The data showcased a 97% objective response rate in the treatment of basal cell carcinoma, highlighting the drug’s potential as a non-surgical treatment option. This advancement underscores Lytix’s innovative oncolytic peptide technology and strengthens its position in the oncology field. Verrica plans to discuss the next steps with the FDA, aiming to develop LTX-315 as a first-line therapy, potentially transforming the treatment landscape for basal cell carcinoma.
More about Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company specializing in the development of innovative therapies using host-defense peptide-derived molecules. Their lead product, LTX-315, is a pioneering oncolytic molecule designed to enhance anti-cancer immunity, with potential applications in various cancer indications and treatment settings.
YTD Price Performance: -3.33%
Average Trading Volume: 2,166
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €33.63M
For an in-depth examination of 6BG stock, go to TipRanks’ Stock Analysis page.